INTRAVITREAL BEVACIZUMAB IN THE MANAGEMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Ophthalmology,General Medicine
Reference29 articles.
1. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration.;Barouch;Int Ophthalmol Clin,2004
2. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.;Ng;Can J Ophthalmol,2005
3. ; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration.;Rosenfeld;N Engl J Med,2006
4. ; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.;Brown;N Engl J Med,2006
5. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascularization age-related macular degeneration.;Rosenfeld;Ophthalmic Surg Lasers Imaging,2005
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression;Journal of Clinical Medicine;2022-01-10
2. Demographic and Clinical Factors that Influence the Visual Response to Anti-Vascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration: A Systematic Review;Ophthalmology and Therapy;2020-08-08
3. Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better;Clinical Ophthalmology;2019-02
Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
4. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN;Retina;2016-05
5. Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies;Drug Safety;2016-03-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3